Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Castration-Resistant Prostate Cancer
NCT01215032Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2010
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liquid metformin (Aspargo Labs) in prostate cancer (PCa), sponsored by Massachusetts General Hospital. Primary endpoint: Prostate Specific Antigen Response at 12 weeks. Started Sep 2010; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01215032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01215032.